Drug Trial Radar · NCT06494488
Differential Thrombogenesis by EPA and DHA Mediated by HDL
Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Aug 1, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- The Miriam HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants will: Visit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.
Conditions
- Lipid Metabolism Disorders
- Hypertriglyceridemia
Interventions
EPADrug
Fish oil
DHADrug
Fish oil
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Platelet Aggregation Area Under the Curve (AUC) Over TimeTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brown University Health - Lipid Clinic
Providence, Rhode Island · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.